Home > Boards > US Listed > Biotechs >

Can-Fite BioPharma (CANF)

CANF RSS Feed
Add CANF Price Alert      Hide Sticky   Hide Intro
Moderator: midastouch017
Search This Board: 
Last Post: 5/13/2021 12:12:03 PM - Followers: 64 - Board type: Free - Posts Today: 0

Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and liver diseases.

The company platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The company compounds bind with nM affinity to the A3AR and initiate de-regulation of the NF-kB and the Wnt signal transduction pathways resulting in anti-inflammatory and anti-cancer effects

 
 

The company pipeline drugs are synthetic, highly specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile. Piclidenoson (CF101), Can-Fite`s lead drug candidate, is an oral drug that has been successfully tested in animal models and is currently in Phase III clinical studies for the treatment of Rheumatoid Arthritis (RA) and Psoriasis. All human clinical studies have demonstrated this drug to have an excellent safety profile. In two Phase II studies where Piclidenoson has been given as a standalone drug, data indicated that it acted as a disease modifying anti-inflammatory drug in RA patients. The Phase II and the Phase II/III clinical studies in Psoriasis showed clinical activity and safety of the drug. Namodenoson (CF102), Can-Fite`s second drug candidate, is an oral drug currently being developed for the treatment of Liver Diseases including hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH). CF602 an allosteric modulator at the A3AR which has shown proof of concept in pre-clinical pharmacology studies and is earmarked for the treatment of sexual dysfunction. Can-Fite has a wealth of clinical experience which includes over 1200 patients who have participated in clinical trials conducted by the company.

Can-Fite has licensed Piclidenoson for the treatment of autoimmune diseases to Cipher Pharmaceuticals in Canada, to Gebro Pharma GmbH in Spain, Switzerland & Austria,  for RA to Kwang Dong in Korea and to CMS for RA and Psoriasis in China, Taiwan, Hong Kong, Macao.

Can-Fite has licensed Namodenoson for the treatment of Liver Cancer and NASH to Chong Kun Dang Pharmaceut in Korea and to CMS in China.

Can-Fite is collaborating with leading researchers from the US NIH and the Leiden University in the Netherlands.

 

Israeli Office

10 Bareket Street
Kiryat Matalon
P.O. Box 7537
Petah-Tikva 49170
ISRAEL (Directions)

Tel: +972-3-9241114
Fax: +972-3-9249378

General email:
info@canfite.co.il

 

Investor Relations
(800)716-4880
info@canfite.co.il 


 

USA Office

255 Bear Hill Road, Suite 2200
Waltham
MA 02451
USA

Tel: +972-3-9241114
Fax: +972-3-9249378

http://www.canfite.com/

 

CANF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CANF News: Can-Fite to Present at Benzinga’s Global Small Cap Conference on May 13, 2021 05/06/2021 07:00:00 AM
CANF News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 04/29/2021 07:08:48 AM
CANF News: Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 04/29/2021 07:00:00 AM
CANF News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 04/23/2021 04:31:57 PM
CANF News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 04/22/2021 07:27:37 AM
PostSubject
#1632  Sticky Note Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma midastouch017 03/16/21 09:07:44 AM
#1664   Any news on the Conf. and presentation? KMBSOUTH 05/13/21 12:12:03 PM
#1663   At least replies to our earlier question on Spideyboy 05/10/21 05:26:01 AM
#1662   Can-Fite to Present at Benzinga’s Global Small Cap midastouch017 05/06/21 07:46:08 AM
#1661   Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; midastouch017 04/29/21 07:54:06 AM
#1660   Can-Fite Expands its Phase II COVID-19 Study to Europe midastouch017 04/22/21 08:10:03 AM
#1659   Can-Fite Starts Preclinical Studies Required By FDA, EMA midastouch017 04/21/21 04:30:55 AM
#1658   Can-Fite initiates preclinical studies of its two lead midastouch017 04/20/21 09:23:10 AM
#1657   Can-Fite Initiates Preclinical Studies Required by FDA and midastouch017 04/20/21 08:25:31 AM
#1656   Thanks for reaching out to CANF and getting midastouch017 04/08/21 04:01:22 AM
#1655   Hi Midas Spideyboy 04/08/21 01:54:25 AM
#1654   Does anybody have ok communications with CANF IR, midastouch017 04/07/21 08:06:14 AM
#1653   And yet even with good news here we sit.... 5SCHIPS 04/05/21 11:14:53 AM
#1652   Can-Fite cannabis compound inhibits liver cancer growth midastouch017 04/05/21 08:28:35 AM
#1651   Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in midastouch017 04/05/21 08:25:01 AM
#1650   Can-Fite Presentation midastouch017 04/04/21 10:50:51 AM
#1649   Can-Fite: Summary of Existing Out-licensing Deals with Potential midastouch017 03/30/21 08:08:01 AM
#1648   I am glad we did not put to qop128 03/27/21 05:12:14 PM
#1647   So it would appear they do have just Spideyboy 03/27/21 03:33:32 AM
#1646   Can-Fite Reports 2020 Financial Results & Provides Clinical midastouch017 03/25/21 09:15:38 AM
#1645   I will tune in to: midastouch017 03/20/21 09:26:31 AM
#1644   Is this a string of news boost midastouch017 03/20/21 08:22:51 AM
#1643   Is this a string of news boost before Spideyboy 03/20/21 06:35:33 AM
#1642   CANF needs some viagra cause it needs to 5SCHIPS 03/19/21 12:06:20 PM
#1641   Can-Fite BioPharma Interview to Air on Bloomberg Television midastouch017 03/19/21 09:21:06 AM
#1640   Can-Fite: Topical Administration of CF602 Fully Recovers Erectile midastouch017 03/18/21 08:26:39 AM
#1639   * * $CANF Video Chart 03-16-2021 * * ClayTrader 03/16/21 04:10:54 PM
#1638   Can-Fite BioPharma / Increase 50% midastouch017 03/16/21 03:15:56 PM
#1637   I think she takes off again. You know The Stock Reader 03/16/21 01:28:34 PM
#1636   crapping out pretty good on the news. madras50 03/16/21 01:20:16 PM
#1635   $CANF all out $4.1 swanlinbar 03/16/21 09:47:47 AM
#1634   Shorts are FIGHTING HARD!! Gotta' KEEP BUYING to Callme RICK 03/16/21 09:39:03 AM
#1633   Can Fite BioPharma L (CANF) mick 03/16/21 09:38:39 AM
#1632   Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma midastouch017 03/16/21 09:07:44 AM
#1631   $CANF is screaming for the top after announcing AlphaStockNews 03/16/21 08:52:23 AM
#1630   Whats the target here $10? The Stock Reader 03/16/21 08:50:28 AM
#1629   Yeah baby Docstemcell2020 03/16/21 08:28:15 AM
#1628   WOOHOOOOOOO CANF$$$$$$$$ weedtrader420 03/16/21 07:29:56 AM
#1627   https://www.wsj.com/market-data/quotes/CANF mick 03/13/21 09:27:24 AM
#1626   Can Fite BioPharma L (CANF) mick 03/11/21 04:06:52 PM
#1625   INTERESTING $CANF mick 03/11/21 04:06:42 PM
#1624   Can-Fite Enrolls First Patient in Phase II COVID-19 midastouch017 03/05/21 08:27:20 AM
#1623   READING MIDAS Can Fite BioPharma L (CANF) mick 02/27/21 12:36:01 PM
#1622   We going to fly, kofikbaz 02/23/21 12:15:08 AM
#1621   Is there any timeline on P3? midastouch017 02/22/21 02:16:59 PM
#1620   Midas...I got to give it to you. You Meshuggah777 02/22/21 01:31:32 PM
#1619   Can-Fite soars 45% on positive namodenoson data in midastouch017 02/22/21 07:53:32 AM
#1618   New Positive Data from Can-Fite’s Liver Cancer Phase midastouch017 02/22/21 07:47:03 AM
#1617   CANF$ $10 TARGET PRICE TODAY WOOHOOOOOOOOOO weedtrader420 02/11/21 08:05:29 AM
#1616   Thanks for the info. Cannabis stocks were moving tone3 02/10/21 05:16:07 AM
#1615   $CANF - Can-Fite BioPharma - Treatment for COVID-19 midastouch017 02/10/21 04:14:54 AM
PostSubject
Consent Preferences